A Case of Lenvatinib-Induced Focal Segmental Glomerulosclerosis (FSGS) in Metastatic Medullary Thyroid Cancer

We describe a case of lenvatinib (E7080) associated focal segmental glomerulosclerosis (FSGS) encountered during the treatment of metastatic medullary thyroid cancer. Proteinuria is a relatively common side effect of VEGF-targeted treatments and can occasionally result in treatment discontinuation....

Descripción completa

Detalles Bibliográficos
Autores principales: Fleming, Kathryn, McGuinness, James, Kipgen, David, Glen, Hilary, Spiliopoulou, Pavlina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6192131/
https://www.ncbi.nlm.nih.gov/pubmed/30402314
http://dx.doi.org/10.1155/2018/6927639

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6192131/
https://www.ncbi.nlm.nih.gov/pubmed/30402314
http://dx.doi.org/10.1155/2018/6927639

Ejemplares similares